AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAY 6 - (NewsRx.com & NewsRx.net) -- A new study finds that screening women 30 years of age or older with both a Pap and HPV (human papillomavirus) test reduces cervical cancer incidence by up to 93% and results in a 30% cost savings compared to the traditional annual Pap exam, Digene Corp. (DIGE) announced.
The research concluded that compared to the traditional annual Pap used alone, routine screening every 2-3 years that includes testing for the human papillomavirus - which causes virtually all cases of cervical cancer - increases protection against the malignancy as well as reduces the average, per-woman lifetime cost associated with screening. Digene's DNAwithPap Test is the only test for high-risk types of HPV approved by the U.S. Food and Drug Administration.
The study appeared in the April issue of Obstetrics & Gynecology.
"This is one of the most comprehensive studies to examine the cost-effectiveness of Digene's high-risk HPV test as part of routine cervical cancer screening," said Evan Jones, chairman and CEO of Digene. "This study clearly documents the test's ability to reduce the risk of cancer, while saving costs for individuals and society as a whole. Thus, an important conclusion of the research is that in women 30 and older, routine HPV screening along with a Pap offers ...
Source: HighBeam Research, Study documents cost-effectiveness of HPV test in cervical cancer...